Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857398 | 0.98 | KDM4E (0.54) | KDM4EGLAMAPTPOLBPLAU | |
| SCHEMBL5285314 | 0.85 | AAK1 (0.49) | KDM4EGLAMAPTPOLBPLAU | |
| SCHEMBL1342696 | 0.80 | RECQL (0.53) | KDM4EGLARAB9AMEN1KMT2A | |
| SCHEMBL1339192 | 0.80 | MAPT (0.46) | MAPTNPC1RAB9AMAPK1HTT | |
| SCHEMBL1342200 | 0.80 | KEAP1 (0.56) | MAPTMEN1KMT2A | |
| SCHEMBL31366603 | 0.79 | RECQL (0.51) | KDM4ERAB9AMEN1KMT2AHPGD | |
| SCHEMBL2079720 | 0.79 | RECQL (0.51) | KDM4ERAB9AMEN1KMT2AHPGD | |
| SCHEMBL5278682 | 0.79 | KEAP1 (0.54) | MAPTMEN1KMT2A | |
| SCHEMBL1342546 | 0.79 | KMT2A (0.47) | MAPTNPC1RAB9AMAPK1HTT | |
| SCHEMBL22823915 | 0.78 | HPGD (0.56) | KDM4EMAPTPOLBHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-1531815-B1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2014-09-24 | — | — | EP | disclosed |
| CN-101130526-B | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK AS | 2013-07-10 | — | — | CN | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| CN-101130526-A | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK AS (DK) | 2008-02-27 | — | — | CN | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| CN-1678311-A | Arylcarbonyl derivatives useful as therapeutic agents | NOVO NORDISK AS (DK) | 2005-10-05 | — | — | CN | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | KDM4E 992/4885GLA 352/4885MAPT 2678/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | KDM4E 992/4885GLA 352/4885MAPT 2678/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | KDM4E 1420/4885GLA 388/4885MAPT 2678/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | KDM4E 992/4885GLA 352/4885MAPT 2678/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | KDM4E 992/4885GLA 352/4885MAPT 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.